RAG-17 is tailored for the SOD1 gene suppression in individuals with ALS having pathogenic mutations. Credit: CC7/Shutterstock. Ractigen Therapeutics has dosed the first subject in the randomised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback